Skip to main content

Table 2 Adverse events during the PPV

From: Feasibility study of personalized peptide vaccination for metastatic recurrent triple-negative breast cancer patients

Adverse event Grade 1 Grade 2 Grade 3 Grade 4
Injection site reaction 42 37   
Constitutional symptom     
  Fever 8 1   
  Malaise 7 3   
  Edema limbs 2 3   
  Pain 5    
  Tumor pain 4 9   
Gastrointestinal     
  Nausea 4    
  Mucositis oral   1   
  Abdominal pain    1  
  Constipation 1 1   
  Diarrhea 2    
Respiratory     
  Dyspnea 5 1 1  
  Cough 5    
  Hoarseness 2    
  Pneumonitis   1   
  Pleural effusion 1    
  Hypoxia   1 2  
Neurological     
  Headache 1 1   
  Dysgeusia 1    
  Dizziness 2 1   
  Peripheral sensory neuropathy 8 2   
  Peripheral motor neuropathy 1    
Endocrine disorder     
  Hypothyroidism   1   
Skin and subcutaneous     
  Pruritis 33 3   
  Urticaria 4 1   
  Reproductive system     
  Vaginal hemorrhage 2    
  Vascular disorders     
  Hot flashes 1    
  Lymphedema   1   
  Hypertension   1   
Blood/Bone marrow     
  Anemia 18 9 2 2
  Hemoglobin increased 1    
  Leukocytopenia 22 11 4  
  Neutropenia 2 6 5 1
  Lymphocytopenia 29 7 12  
  Thrombocytopenia 6   1  
Metabolism and nutrition     
  Anorexia 2    
  Hyponatremia 1    
  Hyperkalemia 3    
  Hypocalcemia 2    
  Hyperglycemia 2    
Laboratory     
  AST increased 14 9 2  
  ALT increased 19 4 2  
  γ-GTP increased 7 3 2  
  ALP increased 6 1 1  
  Hyperbilirubinemia 3 1 1  
  Creatinine increased 10 3 1  
  Cholesterol high 4    
  Hypoalbuminemia 46 7   
  INR increased 1 1 1  
  APTT increased 1    
  1. ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; APTT, activated partial thromboplastin time; γ-GTP, gamma-glutamyl transpeptidase; INR, international normalized ratio; PPV, personalized peptide vaccination.